ValuEngine upgraded shares of NxStage (NASDAQ:NXTM) from a sell rating to a hold rating in a research note published on Monday morning.
Other equities research analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of NxStage from a sell rating to a hold rating in a research note on Wednesday, January 3rd. BidaskClub upgraded shares of NxStage from a strong sell rating to a sell rating in a research note on Monday, February 5th. Two analysts have rated the stock with a sell rating and nine have issued a hold rating to the company’s stock. NxStage currently has an average rating of Hold and a consensus target price of $30.25.
Shares of NASDAQ:NXTM opened at $25.82 on Monday. NxStage has a 12 month low of $20.45 and a 12 month high of $30.80. The firm has a market cap of $1,701.79, a P/E ratio of -371.14 and a beta of -0.01.
A number of large investors have recently made changes to their positions in NXTM. Cowen Inc. acquired a new position in NxStage in the third quarter valued at $1,908,000. Bank of Montreal Can increased its stake in NxStage by 15.5% in the fourth quarter. Bank of Montreal Can now owns 572,868 shares of the medical device company’s stock valued at $13,880,000 after purchasing an additional 77,082 shares during the period. K2 Principal Fund L.P. acquired a new position in NxStage in the fourth quarter valued at $4,921,000. FNY Partners Fund LP acquired a new position in NxStage in the fourth quarter valued at $300,000. Finally, Dumac Inc. increased its stake in NxStage by 65.0% in the fourth quarter. Dumac Inc. now owns 50,000 shares of the medical device company’s stock valued at $1,212,000 after purchasing an additional 19,700 shares during the period. Hedge funds and other institutional investors own 84.14% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3335067/nxstage-nxtm-upgraded-to-hold-at-valuengine.html.
NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for NxStage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage and related companies with MarketBeat.com's FREE daily email newsletter.